LSK BioPharma Announces Preliminary Review of Top-Line Results from ANGEL Study SALT LAKE CITY, USA, June 27, 2019 – LSK BioPharma (LSKB) has completed the unblinding and preliminary review of topline data from its ANGEL Study, a Phase III clinical trial for
SALT LAKE CITY, USA, and SHANGHAI, CHINA, April 8, 2019 -- LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in
SALT LAKE CITY, USA, Feb 12, 2019 -- LSK BioPharma (LSKB, Company) announced that it has reached the pre-specified number of events required for unblinding and analysis of the primary endpoint of overall survival in the ANGEL study, a global
SALT LAKE CITY, USA, Feb 2nd, 2019 – In order to accommodate rapid growth, LSK BioPharma (LSKB, Company) has relocated its corporate headquarters to 2825 E Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 USA. The new offices will
JOB DESCRIPTION Responsible for compliance with applicable procedures. This position will play a key role in preparing US and international regulatory filings. Individual coordinates and supports technical and scientific regulatory activities, researches regulations and guidelines, and maintains and organizes key information
SALT LAKE CITY, USA, Oct 29th, 2018 -- LSK BioPharma (LSKB, Company) announced that it has completed patient enrollment in its pivotal Phase 3 trial, ANGEL, which is evaluating the efficacy and safety of rivoceranib plus Best Supportive Care (BSC)
Director Clinical Strategic Development LSK Biopharma South San Francisco, CA Director Clinical Strategic Development (CSD) provides critical expertise and leadership in the design and planning of integrated development plans for multiple disease indications. CSD drives adoption of innovative approaches and strategic thinking in
SALT LAKE CITY, USA, and SHANGHAI, CHINA, October 21, 2018 -- LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in
SALT LAKE CITY, USA, Oct 1st, 2018 -- LSK BioPharma (LSKB, Company) announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a Phase I/IIa study protocol to investigate the combination of rivoceranib and paclitaxel, “A
Ensure that global regulated clinical studies are compliant and that clinical trials are conducted with company goals, SOPs, Ethics, ICH GCP and global regulatory guidelines. Provide operations management for the planning, execution and reporting of Phase III global clinical trials.
SALT LAKE CITY, USA, June 19, 2018 -- LSK BioPharma (LSKB, Company) announced that enrollment has opened for the APPEASE study, “A phase 1/2 open label study of the safety and efficacy of apatinib [rivoceranib] administered to patients with advanced
Position Scope and Summary LSK BioPharma is searching for a qualified candidate to join our preclinical product development team in South San Francisco. The position will be responsible for planning and monitoring preclinical and DMPK-related projects performed by LSK BioPharma’s vendors/contractors. Roles
Overview We are currently seeking a full-time, office-based CMC Product Manager to join LSK Biopharma. This position will manage and guide our CMC activities for our small molecule drug substance and product programs from preclinical through commercial. If you want an
Overview We are currently seeking a full-time, office-based Regulatory Affairs Manager/Director to join LSK Biopharma. This position will work with our clinical and product development teams to contribute to the strategic planning and preparation of regulatory submissions and supports the formatting,
SALT LAKE CITY, April 16, 2018 – LSK BioPharma (LSKB) today will present a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The poster discloses nonclinical data suggesting a synergistic combination of rivoceranib (apatinib) with
